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Objective: The retinoblastoma gene product is a cell cycle control protein that when inhibited allows cell proliferation to
progress by releasing E2F. Retinoblastoma manipulation has been attempted to prevent intimal hyperplasia (IH) in
injured native vessels by arresting vascular smooth muscle cell proliferation. However, no studies have identified the role,
if any, of retinoblastoma in anastomotic IH formation after prosthetic arterial grafting. The goal of this study was to
describe the relation of retinoblastoma and E2F to anastomotic IH with analyzing retinoblastoma/E2F levels,
retinoblastoma phosphorylation, and transcription of retinoblastoma and E2F in prosthetic arterial grafting.
Methods: Six-mm–diameter expanded polytetrafluoroethylene carotid interposition grafts (n  12) were implanted in
25-kg mongrel dogs. The intervening arterial segments were harvested as controls. The distal anastomoses were harvested
at 14 and 30 days after implantation for immunoblot, messenger RNA (mRNA), and immunohistochemistry analyses.
Tissue homogenate was separated with sodium dodecylsulfate–polyacrylamide gel electrophoresis and probed with
antibody to total retinoblastoma, phosphorylated retinoblastoma at serine 795, serine 780, and serine 807/811, and
E2F-1. Bands at each time point were quantitated and compared with control artery (n 12). Each lane was standardized
with reprobing with antibody to -tubulin. Immunohistochemistry was performed with antibody to retinoblastoma.
Retinoblastoma and E2F mRNA expression levels in anastomotic IH and control artery were analyzed with an
oligonucleotide microarray.
Results: Total retinoblastoma, from immunoblot analysis, was decreased at the 14-day and 30-day distal anastomoses by
35.7% and 33.6%, respectively, compared with control (P < .01). Furthermore, retinoblastoma at these time points was
unphosphorylated at phosphorylation sites serine 795, serine 780, and serine 807/811. E2F-1 levels at 14 days and 30
days were unchanged compared with control. Positive staining for retinoblastoma was seen in endothelial and vascular
smooth muscle cell from control, 14-day, and 30-day tissue. A qualitative decrease appeared to be seen in retinoblastoma
in the neointima at 14 and 30 days compared with the native wall. No differential expression of retinoblastoma and E2F
mRNA was seen in anastomotic IH compared with control.
Conclusion: This study showed that total retinoblastoma levels are decreased and E2F-1 levels remain unchanged in
anastomotic IH. Attenuated retinoblastoma is a novel concept to anastomotic IH after prosthetic arterial grafting.
Retinoblastoma/E2F imbalance may not be the result of transcriptional regulation and may increase unbound E2F to
promote cell proliferation. Hypophosphorylation of remaining retinoblastoma may minimize uncontrolled proliferation
by preventing further increases in unbound E2F. Therefore, retinoblastoma/E2F imbalance may lead to the early but
limited increase in cell proliferation seen after prosthetic arterial grafting and appears to contribute to the development
and progression of anastomotic IH. (J Vasc Surg 2002;35:1233-41.)
Anastomotic intimal hyperplasia (IH) is a significant
cause of morbidity in patients with peripheral arterial pros-
thetic bypass grafts.1 IH involves the migration and prolif-
eration of vascular smooth muscle cells into the neointima
with extracellular matrix elaboration. Cell proliferation is
controlled by various extensively regulated cell cycle pro-
teins and is a key feature in vascular injury and anastomotic
IH.2 One of these cell cycle control proteins is the retino-
blastoma gene product. Retinoblastoma, a 928–amino acid
nuclear phosphoprotein, was first discovered as a tumor
suppressor gene. It is relatively constant in a given cell
type.3 Also, it plays a fundamental role in cellular regulation
by controlling the restriction point of the cell cycle—the
G1 to S phase transition.4 Retinoblastoma prevents the cell
from progressing through the restriction point by binding
to the transcription factor E2F.5 E2F is a group of closely
related proteins (E2F-1 to 5) that heterodimerize with
another set of transcription factors (DP-1 to DP-3) to form
functionally active DNA binding complexes.6 E2F regu-
lates the expression of numerous genes necessary for the S
phase of the cell cycle, such as thymidine kinase and dihy-
drofolate reductase7 (Fig 1).
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The retinoblastoma/E2F interaction is the key to cell
cycle regulation at the restriction point. The principal
mechanism for retinoblastoma regulation is determined by
its phosphorylation status.3 Approximately 16 different
potential amino acid groups are identified on retinoblas-
toma that may be phosphorylated. Sites that may regulate
the retinoblastoma/E2F interaction include serine 795,
serine 780, serine 807/811, serine 249/252, and threo-
nine 373.3 Phosphorylation occurs via cyclin/cyclin-
dependent kinase (cdk) complexes. cdks are tightly regu-
lated by cdk inhibitors.8 Retinoblastoma in the
hypophosphorylated state binds E2F, thus preventing E2F
from binding to promoter regions on DNA to commence
transcription. However, when a cyclin/cdk complex as the
result of an extracellular signal phosphorylates retinoblas-
toma, retinoblastoma is rendered inactive and released
from the E2F complex.9 This creates “free” E2F that has
the ability to bind to DNA. Although phosphorylation is
the principal mechanism for regulating retinoblastoma,
controlling the level of total retinoblastoma is another
avenue for modulation. In fact, retinoblastoma has been
shown to be degraded by the ubiquitin/proteasome path-
way,10 posttranslationally modified,11 and decreased over-
all by altering levels of transcription.12
Although retinoblastoma is well studied, its role in
anastomotic IH formation at the graft/artery interface after
prosthetic arterial grafting has not been characterized. Re-
cently, genetic and pharmacologic manipulation of retino-
blastoma and the retinoblastoma/E2F interaction has been
attempted to diminish IH in arterial injury models by
increasing active, hypophosphorylated retinoblastoma lev-
els.13,14 Although these interventions have resulted in ap-
parent attenuation, they are not applicable to prosthetic
arterial grafting. IH from native arterial injury, although
morphologically similar, is different from anastomotic IH
from prosthetic arterial grafting.15 Thus, studies have yet to
identify a mechanistic role, if any, of retinoblastoma or of
altered retinoblastoma function in the formation of anasto-
motic IH. The goal of this study was to identify the role of
retinoblastoma and the retinoblastoma/E2F interaction in
the formation of anastomotic IH at various time points
after prosthetic arterial grafting by investigating retinoblas-
toma/E2F protein levels, retinoblastoma phosphorylation
status, and differential messenger RNA expression of retino-
blastoma and E2F in anastomotic tissue. This study inves-
tigates the graft/artery interface as a single entity rather
than its individual cell types because there is constant
interaction among all cell types at the anastomosis that
leads to IH.
MATERIALS AND METHODS
General materials. Six mongrel dogs (25 kg) were
used. Animal protocols received institutional approval. Animal
care complied with guidelines from the National Society for
Medical Research and the National Insitutes of Health.16
Expanded polytetrafluoroethylene grafts were obtained from
W. L. Gore & Associates, Inc (Newark, Del). Cell lysis buffer
(20 mmol/L Tris-HCl, 150 mmol/L NaCl, 1 mmol/L Na2
ethylenediamine tetraacetic acid, 1 mmol/L ethyleneglycol-
bis-[-aminoethylether]-N,N,N’,N’-tetraacetic acid, 1%
Fig 1. Retinoblastoma/E2F pathway. Retinoblastoma gene product (Rb) in its active unphosphorylated state binds
E2F/DP heterodimeric complex lengthening time spent in G1. Via extracellular signals, a cyclin/cdk complex becomes
active and phosphorylates retinoblastoma. This results in retinoblastoma inactivation and release from E2F/DP. E2F
complex is now able to initiate transcription of S phase genes. Phosphorylation can be inhibited with cdk inhibitors or
protein phosphatase 1. Retinoblastoma levels can possibly be regulated with degradation through ubiquitin/protea-
some pathway.
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Triton, 2.5 mmol/L sodium pyrophosphate, 1 mmol/L
-glycerophosphate, 1 mmol/L Na3VO4, 1 g/mL leu-
peptin, and 1 mmol/L phenylmethylsulfonyl fluoride),
antibodies to C-terminal retinoblastoma and retinoblastoma
phosphorylation sites serine 795, serine 780, and serine
807/811, horse radish peroxidase (HRP)–conjugated sec-
ondaryantibody,biotinylatedmolecularweightmarker,HRP-
conjugated biotin antibody, standard retinoblastoma protein,
and positive and negative controls for phosphorylated retino-
blastoma were obtained from Cell Signaling Technologies
(Beverly, Mass). Hela cell lysates (positive control), antibody
to E2F-1, and -tubulin were obtained from Santa Cruz
Biotechnology, Inc (Santa Cruz, Calif). Laemmli buffer 
5% -mercaptoethanol, electrode buffer (Tris/glycine/
sodium dodecylsulfate), transfer buffer (Tris/glycine),
Tris-buffered saline solution (TBS), TBS  0.1% Tween
(TBST), blocking buffer (TBST  5% nonfat dry milk),
antibody dilution buffer (TBST  5% bovine serum
albumin), 7.5% Tris-HCl sodium dodecylsulfate gels, and
nitrocellulose membrane were obtained from Bio-Rad
(Hercules, Calif). Enzymatic chemiluminescence western
blotting detection chemiluminescent reagent was obtained
from Amersham Pharmacia (Piscataway, NJ).
Graft placement and harvest. Animals were sedated
with acepromazine maleate by mouth and intubated with
intravenous pentobarbital. Continuous 1% halothane gas
anesthesia was maintained throughout the procedure.17,18
A midline neck incision was made, and both carotid arteries
were dissected free, yielding segments approximately 10 cm
in length. After heparinization (100 U/kg), the interven-
ing carotid artery was excised and immediately snap frozen
in liquid N2 as previously described (n  12).
17,18 This
native carotid artery segment served as a baseline control to
minimize any global confounding effects from systemic
inflammatory response to surgery or foreign body intro-
duction on the vasculature. Bilateral standard tapered end-
to-end anastomoses were constructed with 6-mm (internal
diameter) expanded polytetrafluoroethylene grafts and 6-0
prolene sutures. Both arteries were grafted to optimize
retinoblastoma protein yield. Initial patency of grafts was
established with palpation. At 14 and 30 days after implan-
tation, 2-cm distal anastomotic segments were excised (n
6/time point) and the animal was killed. These anasto-
motic segments contained all layers of the vessel wall and
any tissue extending into the graft. All grafts were patent at
the time of anastomotic harvest. A small segment of the
distal anastomosis was retained for histologic analysis. The
remaining tissue was immediately frozen in liquid N2 and
stored at –80° C before total protein and RNA isolation.
The 14-day and 30-day time points were chosen to inves-
tigate the healing patterns after prosthetic arterial grafting
without the associated acute inflammatory response to
surgery. A prior study of cyclin marker expression has
shown cell proliferation is present but reduced at 14 and 30
days.19 Furthermore, maturity of lesion formation in anas-
tomotic IH is, if ever, usually not achieved until 2 to 3
months.20
Immunoblot analysis. Tissue was homogenized with
cell lysis buffer, sonicated, and centrifuged at 14000g for
15 minutes at 4° C. Supernatant protein concentration was
measured with a standard Lowry assay. Protein, 75 g, was
diluted in Laemmli buffer and loaded into each lane of gel
for sodium dodecylsulfate–polyacrylamide gel electro-
phoresis in electrode buffer (n  12 lanes/time point).
Gels also were loaded with standard retinoblastoma pro-
tein, positive and negative controls for phosphorylated
retinoblastoma, and hela cell extract for a positive lysate
control. Gels were run at 120V for 60 minutes and trans-
ferred to nitrocellulose with wet transfer technique at 100V
for 60 minutes. The membrane was blocked for 1 hour at
25° C, incubated overnight with primary antibody at 4° C,
and washed in TBST. The membrane was incubated with
HRP-conjugated secondary antibody and anti-biotin anti-
body in blocking buffer for 1 hour at 25° C. Protein was
detected with enzymatic chemiluminescence agent and ex-
posed to Kodak Biomax ML film (Rochester, NY). Blots
were subsequently washed in TBST, stripped for 30 min-
utes at 50° C, and reprobed as previously mentioned with
antibody to -tubulin to standardize lanes and ensure equal
protein loading as previously described.21,22 Bands were
quantitated with a digitizing scanner and National Insitutes
of Health Image 6.0 software. Data were expressed as mean
retinoblastoma:-tubulin ratio SE. Protein was analyzed
for total retinoblastoma (c-terminus antibody), phosphor-
ylation status of retinoblastoma (antibody to serine 795,
serine 780, and serine 807/811; sensitivity: 5 to 10 ng of
retinoblastoma), and E2F-1. These antibodies were devel-
oped for human proteins but have wide reactivity with
other mammals (per manufacturer), and their targets are
highly conserved among species.23
Immunohistochemistry. Immunohistochemistry was
performed with monoclonal antibody to the C-terminus
of retinoblastoma (Oncogene Research Products, Boston,
Mass) on control, 14-day, and 30-day tissues. Sections were
adhered to poly-l-lysine–coated slides, deparaffinized, hy-
drated, antigen retrieved with citric acid/sodium citrate,
blocked, and incubated with primary antibody overnight at
4° C. After incubation with primary antibody, sections
were rinsed in phosphate-buffered saline solution  1%
bovine serum albumin. Species-appropriate biotinylated
secondary antibody was applied, followed by avidin-biotin
peroxidase complexes (ABC Elite Kits, Vector Laborato-
ries, Inc, Burlingame, Calif). Antibody presence was iden-
tified with diaminobenzidine/peroxidase and counter-
stained with hematoxylin. Omission of primary antibody
served as the negative control. Antibody also was tested on
canine and human colon samples to ensure equivalent
immunostaining between the two species.
Gene array. To determine the transcriptional levels of
retinoblastoma and E2F in anastomotic IH at 14-day and
control artery, the Affymetrix Human Genome U95A gene
chip expression analysis probe array (Affymetrix, Inc, Santa
Clara, Calif), an oligonucleotide microarray, was chosen (n
3). It represents approximately 12,560 sequences from the
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UniGene database. The sensitivity of the assay was detection
of 1 transcript in 100,000.
The use of canine tissue on a human array is not
problematic in this study because retinoblastoma and E2F
are highly conserved among mammalian species.23 The
RNA sequences should be the same or have a very high
homology, making use of this chip appropriate for this
study. This animal model emulates human healing pat-
terns,24 so differential expression should be similar. Fur-
thermore, the gene array has many internal controls to
ensure that the hybridization seen is not artifactual, ran-
dom, or representative of similar sequences on another
gene. Each gene on the array is represented by 20 oligonu-
cleotide probe pairs consisting of a perfect match and single
mismatch oligonucleotide. The average intensity difference
between the match/mismatch pair depicts the expression
level for a specific probe. Multiple probes per gene and the
mismatch base pair ensure the authenticity of hybridiza-
tion. Furthermore, common housekeeping genes on the
array were used as a reference to confirm the hybridization
seen for retinoblastoma and E2F was true. Genes already
known to be differentially expressed, like collagen, were
observed to provide further validity to the experiment.
Finally, microarray results are not quantitative but provide
a screening tool for further investigation.17 Tissue was
homogenized and RNA was extracted with the Qiagen
RNeasy minikit (Valencia, Calif). RNA from hyperplastic
and control samples was labeled, fragmented, hybridized,
and scanned25 by a core facility. Data were analyzed with
GeneChip 3.1 expression analysis software (Affymetrix)
and imported into Microsoft Excel. Significant differential
expression was defined as a more than two-fold change as
recommended by the manufacturer.
Statistical analysis. The one-way analysis of variance
was used for statistical analysis of immunoblots. Significant
data underwent post hoc testing with the Tukey/Kramer
significant difference test. A P value of less than .05 was
considered significant.
RESULTS
Total retinoblastoma levels. The first aspect of this
study investigated the total amount of retinoblastoma
(phosphorylated and unphosphorylated) that was present
at the distal anastomosis harvested at 14 days and 30 days
compared with control artery. Immunoblot analysis with
antibody to the C-terminus of retinoblastoma showed a
reduction in the total amount of retinoblastoma at 14 days
and 30 days compared with control (Fig 2 , A). Control
carotid artery had a retinoblastoma:-tubulin ratio of
2.77  0.24. The 14-day tissue had a retinoblastoma:-
tubulin ratio of 1.78  0.11 (P  .01), and the 30-day
tissue had a retinoblastoma:-tubulin ratio of 1.84  0.16
(P  .01). Thus, 14-day and 30-day distal prosthetic arte-
rial graft anastomoses were decreased in total retinoblas-
toma by 35.7% and 33.6%, respectively, compared with
control carotid artery (P  .01). Similar results were ob-
tained in separate studies analyzing the proximal anastomo-
ses (data not shown).
Retinoblastoma phosphorylation status. Although
retinoblastoma was decreased, investigation of the phos-
phorylation status of retinoblastoma was necessary because
this determines functionality. With antibody to the phos-
phorylation sites serine 795, serine 780, and serine 807/
811, retinoblastoma was found unphosphorylated at these
sites in 14-day and 30-day tissue compared with control
(Fig 2 , B), suggesting that any remaining retinoblastoma
was active. One concern was that the amount of phosphor-
ylated retinoblastoma might be extremely reduced. There-
fore, the antibody may not be sensitive enough to detect
phosphorylated retinoblastoma sites in raw cell lysates (an-
tibody sensitivity: 5 to 10 ng of retinoblastoma, per manu-
facturer). Increasing the quantity of cell lysate to 300 g
per lane yielded similar results (results not shown). Immu-
noprecipitation of up to 2-mg cell lysate with antibody to
total retinoblastoma yielded approximately 0.5-g purified
retinoblastoma protein. Immunoblot of 0.5 g of the
purified retinoblastoma protein with antibody to the previ-
ous phosphorylation sites yielded identical results.
Total E2F-1. We sought to see whether any alteration
in E2F-1 levels could account for increased cell prolifera-
tion in anastomotic IH. With antibody to E2F-1, which
detects bound and unbound protein, E2F-1 maintained
equivalent levels in 14-day and 30-day tissue compared
with control carotid artery (Fig 2 , C).
Immunohistochemisty of 14-day and 30-day anas-
tomotic intimal hyperplasia. Tissue samples from 14-day
and 30-day tissue were incubated with antibody to the
C-terminus of retinoblastoma after antigen retrieval tech-
niques. Both 14-day and 30-day tissue showed positive
staining for retinoblastoma in vascular smooth muscle cells
and endothelial cells. Furthermore, retinoblastoma was
qualitatively decreased in the neointima at these two time
points compared with the adjacent media (internal control)
and media of control carotid artery. Removal of primary
antibody (negative control) showed no staining. Positive
control staining by the antibody was confirmed by compar-
ing canine with human colon samples that showed identical
staining patterns. These qualitative results support the im-
munoblot quantitative analysis (Fig 3).
Retinoblastoma and E2F transcription in anasto-
motic intimal hyperplasia. The microarray clearly indi-
cated retinoblastoma, E2F-1, E2F-2, E2F-4, and E2F-6
were not differentially expressed in anastomotic IH com-
pared with control carotid artery at 14 days (differential
expression  two-fold). The array results were validated
with analysis of internal controls and illustration of the
upregulation of collagen in anastomotic tissue. At 14 days,
type I, type II, and type IV collagen was upregulated in
anastomotic IH by 14.4-fold, 6.0-fold, and 3-fold to
8-fold, respectively, compared with control. In a separate
study at 7 days, type III collagen was upregulated in anas-
tomotic IH by 3.9-fold compared with control, similar to
the findings of Cordero et al.18
JOURNAL OF VASCULAR SURGERY
June 20021236 Sivamurthy et al
DISCUSSION
Retinoblastoma is critical to regulating the G1 to S cell
cycle restriction point. In anastomotic IH, the role of
retinoblastoma has not been previously described. Garriga
et al3 and Forte et al26 studied the retinoblastoma protein
family and IH with a rat arterial injury model. In their
models, they found no difference in retinoblastoma com-
pared with control. However, they only studied early time
points. Those results may be related to the acute inflamma-
tory response to surgery. This study describes the relation
of retinoblastoma to anastomotic IH from prosthetic arte-
rial grafting at 14 and 30 days in an animal model that
emulates human healing patterns.24 Furthermore, rather
than investigating each cell type at the graft/artery in-
Fig 2. Immunoblot analysis of total retinoblastoma, phosphorylated retinoblastoma (Rb), and E2F-1 at distal
anastomosis. A, Total retinoblastoma levels as determined with antibody to C-terminus of retinoblastoma in 14-day
and 30-day distal anastomoses and control carotid artery. Total retinoblastoma is decreased in 14-day and 30-day tissue
compared with control. B, Phosphorylation status of retinoblastoma in 14-day and 30-day distal anastomoses and
control carotid artery. Retinoblastoma is unphosphorylated compared with control at serine (Ser) 795, serine 780, and
serine 807/811. C, E2F-1 levels in 14-day and 30-day distal anastomoses and control carotid artery. E2F-1 levels were
maintained in hyperplastic tissue compared with control. All blots were reprobed with antibody to -tubulin to confirm
equal protein loading in each lane. N 12 lanes/time point. MW, Molecular weight marker lane;, 1 positive control
hela cell lysate.
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terface in an in vitro model, we studied the anastomosis
and native artery as an integrated entity, emphasizing the
important collective contribution to IH of endothelial,
native, and hyperplastic smooth muscle and adventitial
cells. This approach is justified because retinoblastoma is
at least expressed by endothelial cells and vascular smooth
muscle cells as shown with immunohistochemistry. However,
further investigation of retinoblastoma is needed in each cell
type to help characterize its contributions to IH.
In this study, total retinoblastoma was decreased at 14
and 30 days (Fig 2). This finding represents a potential area
for retinoblastoma regulation other than phosphorylation,
its principal mode of modulation (Fig 1). Furthermore, an
associated imbalance was seen between retinoblastoma and
its target E2F that may contribute to anastomotic IH.
Normally, retinoblastoma levels remain constant
throughout the cell cycle, even though the total amounts of
retinoblastoma in each cell are specific for a given cell
type.3,27 Thus, retinoblastoma activity and its binding to
E2F are primarily determined by phosphorylation and not
its total levels. However, in this study, total retinoblastoma
was decreased at 14 and 30 days compared with control
from immunoblot and immunohistochemistry analysis. In
fact, retinoblastoma may actually be lower than observed
because the cells are heterogeneously synchronized and
native artery is included in the sample.3 On the basis of
prior studies in different models, retinoblastoma quantity
in IH should be similar to control.27 Our finding of de-
creased retinoblastoma suggests that less retinoblastoma is
available to bind E2F, leaving free E2F to initiate cell prolif-
Fig 3. Immunohistochemistry of 14-day and 30-day distal anastomoses for retinoblastoma gene product. Cross
sections of canine carotid expanded polytetrafluoroethylene graft anastomoses harvested at 14 and 30 days after
implantation were exposed to antibody to C-terminus of retinoblastoma, which represents total Rb protein. Sections
were stained with diaminobenzidine/peroxidase and counterstained with hematoxylin. Immunoreactivity is indicated
with brown staining. A, Cross section (100) at graft-artery interface. Arrows depict internal elastic lamina. Neointima
is above internal elastic lamina, and native artery (internal control) is below. Vascular smooth muscle cells and
endothelial cells show immunoreactivity. Qualitatively decreased immunoreactivity is seen in neointima compared with
native artery. B, Cross section of neointima extending into graft (400). Immunoreactivity for retinoblastoma is still
diminished compared with control.
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eration. Although not a primary mechanism for retino-
blastoma regulation, altering levels may appear to have a role
in retinoblastoma/E2F interactions.27 Retinoblastoma may
be reduced below a threshold level that is necessary for proper
cell cycle exit, leading in part to anastomotic IH. This phe-
nomenon has been shown in skeletal muscle differentiation.28
Recent retinoblastoma-/- knockout models have a consistent
defect in terminal differentiation needed to ensure irreversible
cell cycle withdrawal. In retinoblastoma-/- embryonic fibro-
blasts, cells had a shortened G1 phase and activation of E2F
responsive genes.29 Conversely, increasing retinoblastoma
levels led to a decrease in IH from native arterial injury.13
The mechanism by which retinoblastoma is diminished is
unknown. The microarray data from this study suggest that
regulation of retinoblastoma levels may not occur at the
transcriptional level. More likely, this is a translational or
posttranslational event. Boyer, Wazer, and Band10 and
Scheffner et al30 have shown that retinoblastoma protein
levels decreased in the absence of any change in retinoblas-
toma messenger RNA expression in vivo. Boyer, Wazer,
and Band10 also showed with methionine labeling that
decreased retinoblastoma is not a result of decreased syn-
thesis. Furthermore, in vivo loss of retinoblastoma in im-
mortalized cells results in enhanced degradation with the
ubiquitin/proteasome pathway.10,30 This polymorphic
type of modulation needs further investigation but empha-
sizes the importance of posttranslational modification other
than phosphorylation in the regulation of retinoblastoma.
This study also shows the altered relation between retino-
blastoma and E2F in anastomotic IH. Retinoblastoma/
E2F association determines whether the cell is driven to
proliferation or senescence. E2F-1 levels remained at the
same steady levels as control (Fig 2). Steady E2F levels with
a decrease in retinoblastoma in anastomotic IH compared
with control suggest an imbalance between the two. This
imbalance drives proliferation as described earlier. Of note,
most E2F-1 is in its free form in the cell,31 such that any
decrease in retinoblastoma leads to more free E2F. Over-
expression of E2F in quiescent fibroblasts has been shown
to induce premature S phase and inhibit terminal differen-
tiation,32 and its absence leads to a delayed S phase.33
Similar results are also seen in knockout studies. Retinoblas-
toma-/- with wild type E2F had an increased frequency of
tumors compared with retinoblastoma-/- with E2F-/-.34 Lit-
tle is known about the actual molar ratios of retinoblasto-
ma/E2F, but the relative amounts are more important.
The relative differences in retinoblastoma/E2F in anasto-
motic IH compared with control suggest this balance may
be essential to maintaining quiescence. Retinoblastoma
should increase in parallel with increases in free E2F. The
ratio of free E2F to retinoblastoma/E2F is critical in the
decision to continue proliferation and pass the restriction
point.35 In fact, the silencing of genes in cell cycle progres-
sion is determined by the active repression of retinoblasto-
ma/E2F or absence of free E2F.27 Further studies are
needed to address the interaction between retinoblastoma
and E2F in anastomotic IH.
Study of retinoblastoma would not be complete with-
out comment on its phosphorylation status in anastomotic
IH. In a proliferative state, more retinoblastoma would be
expected to be phosphorylated. Interestingly, retinoblas-
toma in anastomotic IH was hypophosphorylated. Several
reasons can account for the results seen. First, only four of
16 phosphorylation sites on retinoblastoma were studied.
These sites may not be involved in regulating retinoblas-
toma function as it relates to E2F-1. Indeed, phosphoryla-
tion involves a complex regulation. Phosphorylation of
specific sites appears to regulate distinct retinoblastoma
function. In fact, initial phosphorylation may lead to in-
creased hypophosphorylated active protein.9 Furthermore,
other phosphorylation sites not studied may be integral to
retinoblastoma function. Further study of remaining sites is
ongoing. Another possibility is that decreased phosphory-
lation triggers autorepression of retinoblastoma,12 which
may lead to increased degradation of retinoblastoma.
Alternatively, asynchronously growing cells in anasto-
motic IH may have, on average, low phosphorylation rates.
Also, the population of cells in the neointima is so small that
phosphorylation may not be detected with the assays used.
Another consideration is that a fundamental defect in reti-
noblastoma phosphorylation may exist.9 In the context of
diminished quantities of total retinoblastoma in this study,
dephosphorylating remaining retinoblastoma may repre-
sent a mechanism by which the remaining retinoblastoma
limits uncontrolled proliferation by preventing transforma-
tion and allowing only a small pool of free E2F with the
ability to drive some proliferation. In fact, knockout studies
of retinoblastoma show uncontrolled proliferation and chi-
meras show decreased but existent proliferation.36 Thus,
decreased retinoblastoma that is hypophosphorylated may
increase cell proliferation while regulating the extent of
proliferation.
A potential criticism of this study could be the selection
of time points. Hamdan et al19 showed diminished cell
proliferation at 14 days and further decreases at 30 days
with immunohistochemistry with a cyclin-specific anti-
body. From their study, one would expect retinoblastoma
to be increased at 30 days compared with 14 days. That
study qualitatively looked only at one mediator of the cell
cycle with immunohistochemistry. In addition, although
their study showed minimal proliferation at 30 days, pro-
liferation still existed. However, the cell cycle is complex
and regulated by many different factors so that a decrease in
one cell cycle regulator does not imply a global change in all
mediators. Also, the anastomosis is an area of chronic injury
involving continuous remodeling of both its cellular and
extracellular matrix components, necessitating cell turn-
over15 and matrix degradation with lesion homeostasis not
being achieved, if ever, until 2 to 3 months.20 Thus, our
study of IH at these time points is appropriate and mini-
mizes the influence of the acute inflammatory response to
surgery.
In summary, total retinoblastoma is diminished in anas-
tomotic IH. This attenuation may not be a result of de-
creased transcription and may be accomplished with post-
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translational modifying mechanisms. By decreasing
retinoblastoma while maintaining normal E2F levels, the
retinoblastoma/E2F interaction is at an imbalance and may
lead to entrance into S phase of the cell cycle, promoting
cell proliferation. Furthermore, the remaining retinoblas-
toma is active, potentially limiting the extent of uncon-
trolled proliferation. Therefore, retinoblastoma/E2F im-
balance appears to mechanistically contribute to the
development and progression of anastomotic IH and pro-
vides additional support for modulation of their levels to
attenuate anastomotic IH from prosthetic arterial grafting.
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DISCUSSION
Dr Colleen Brophy (Phoenix, Ariz). I am not surprised that
there was no change in transcriptional regulation because what you
really demonstrated is that there is a decrease in the phosphoryla-
tion. Have you looked upstream then at the cyclin kinase complex
that phosphorylates retinoblastoma (Rb) to see if that is what has
changed in your lesions?
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Dr Nayan Sivamurthy. Thank you, Dr Brophy, for your
remarks. We have not looked at the cyclin-dependent kinase com-
plexes. Part of our next project is to look at the upstream effectors
of Rb to see whether upregulation or downregulation of certain
cyclin/cdk is contributing to the results shown here. However,
there is evidence to suggest that this attenuation of Rb, which has
been described in several other systems, may be related to the
ubiquitin/proteasome pathway. Rb may be degraded through this
process and not influenced by kinases explicitly in anastomotic
intimal hyperplasia.
Dr Michael Conte (Boston, Mass). Nayan, that was nicely
presented. I have two questions. I am trying to synthesize this. As
I understand it, you are showing that Rb is not phosphorylated,
but in fact we would expect that cells that are progressing through
the cell cycle would have phosphorylation of Rb; in fact, that is a
precondition. I am a little bit perplexed by the disconnect. In your
model, are you suggesting that the overall level of Rb is a way in
which the cell controls moving through the cell cycle? And if that
is true, how? Are you suggesting that transcriptional regulation of
Rb is a way that the cell controls the cell cycle or degradation of Rb?
Can you explain those two aspects of the work?
Dr Sivamurthy. Thank you, Dr Conte. This work suggests
that the overall level of Rb is another method to control the cell
cycle at the G1 to S transition. What I am trying to postulate is that,
in most quiescent cells, most of the cells have free E2F. My
hypothesis is that by decreasing the total levels of Rb, there is less
Rb available to bind to E2F and prevent E2F from initiating the S
phase. Basically, there is an altered balance between Rb and E2F
promoting cell proliferation.
Dr Conte. How does that occur? How would the cell de-
crease—how do you hypothesize?
Dr Sivamurthy. That is one of the areas we are trying to look
at. Our differential expression results suggest that the changes in
Rb levels may not be through increased or decreased transcription
of mRNA for Rb. There are several papers that have described Rb
degradive processes, like the ubiquitin/proteasome pathway, in
other cell types. This pathway may be the likely mechanism. Recent
published results from our lab show that by inhibiting the protea-
some, vascular smooth muscle cell proliferation is inhibited.
Dr Mannick. Just to follow up a bit on the point that Dr
Conte was making. In terms of the technique you used to try to
determine mRNA levels, why on earth put dog mRNA—was this a
human gene chip?
Dr Sivamurthy. Yes, it is.
Dr John Mannick (Boston, Mass). Dog mRNA on a human
gene chip to try to decide what is expressed. Why not just do
reverse transcriptase–polymerase chain reaction, which might very
well have shown a difference? I would be sort of skeptical that you
really know whether or not message was up, down, or sideways
with the test you used.
Dr Sivamurthy. Thank you, Dr Mannick. The reason we are
illustrating the gene chip results is that it is a chip that we are using
in our lab in a broader sense to look at differential expression in
anastomotic intimal hyperplasia versus control. The data happened
to be available on these chips to look at these two specific genes.
Gene chips provide a quick, simple, and accurate method for
screening the genome to determine differential expression and if
repeated several times, like in this study, can produce results similar
to reverse transcriptase–polymerase chain reaction.
Now the issue of using dog mRNA and a human chip—first, I
would suggest that Rb is a highly conserved protein and its RNA is
highly conserved among mammalian species. It is also very com-
mon and present in almost all cells. The Rb genetic sequence in
dogs should be very similar if not the same as the human sequence.
We would not want to use the chip analysis for an obscure gene.
Second, the chip itself has many internal controls. Each gene
represented contains 20 oligonucleotide probe pairs. You must
have a match to a majority of those oligonucleotide probes in order
for there to be truly significant expression of that gene. Further-
more, within the oligonucleotide probe pair, there is a mismatch
base pair in one of the oligonucleotides so that when RNA bind to
both pairs we can be assured that the hybridization that we are
seeing is true. Third, we also looked at several other genes like
collagen that have been shown to be upregulated in intimal hyper-
plasia and that correlated with our results on the chip. Fourth, our
dog model is unique in that the healing patterns after vascular
injury mimic human healing patterns so it could possibly be
appropriate to use cross species on these chips.
Finally, it must be stressed that the gene chip was not exclu-
sively used to monitor the expression of the genes studied here.
That would be insufficient. Gene chips are part of a global project
in our lab to look at differential expression in anastomotic intimal
hyperplasia. Rb and E2F happened to be represented on these
chips. It should also be pointed out that gene chip analysis repre-
sents a screening tool for raising new hypotheses and starting
points in research and a relatively new technology with difficulty in
interpreting the results. Many studies have shown its reliability
compared with other methods of studying differential expression.
For these reasons, we feel that a human gene chip on a canine
model is applicable and credible in this scenario.
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